SentryX is a late preclinical stage biopharmaceutical company developing a non-opioid platform for the treatment of acute pain after surgery. SentryX was founded in 2017 as a spin-out from the University Medical Center Utrecht, where co-founder prof. Jorrit-Jan Verlaan works as a spine surgeon.
Both professionally and personally, Jorrit-Jan had experienced the intense acute pain patients suffer after musculoskeletal surgery. Because of the many drawbacks of the systemic, opioid-based pain treatments we use today, he wanted to radically change the approach towards more local strategies. To this end, he partnered with entrepreneur Bas Oosterman and founded SentryX in 2017. With their team, they developed a local non-opioid pain treatment for patients undergoing musculoskeletal surgery. SentryX’s lead product, BR-003, is currently being brought up to GxP standards leading up to human clinical testing.
SentryX is a dynamic team with people from different personal and professional backgrounds who enjoy taking the initiative and coming up with creative solutions for complex problems. People with technical, clinical, and regulatory expertise work together to bring local therapies from the bench to the bedside.
Co-founder and Chief Scientific Officer
“Co-founder and Chief Scientific Officer Jorrit-Jan (JJ) Verlaan is a spine surgeon from the University Medical Center Utrecht with a special interest in improving clinical outcome by tailoring treatment through a multidisciplinary approach. With his team, he developed innovative surgical and non-surgical procedures that have been published and adopted worldwide for the benefit of, especially, cancer patients. Professor Verlaan is past chairman of the Research and Innovation Committee of the Dutch Orthopedic Association and currently serves as co-director of the Orthopedic residency program and is also a member of the AO Spine Tumor Knowledge Forum.”
Co-founder and CEO
“Co-founder and CEO Bas Oosterman has gained a multi-disciplinary background at various innovative companies. Before starting SentryX he served as Chief Operating Officer of a Clinical Research Organisation and worked for Philips Electronics in various positions. He studied Econometrics, received his PhD degree in Management and Organization, and is a (six sigma) Black Belt. His PhD thesis dealt with speeding up the time-to-market of new product innovation projects.”
“Marianna Tryfonidou is a professor in regenerative orthopedics at the Utrecht University. She is a certified veterinary surgeon for companion animals and has expertise in translational research. She coordinates the iPSpine consortium that was recently awarded €15 million under the Horizon 2020 program developing an advanced therapy for chronic low back pain.”
“Raymond Schiffelers is professor of Nanomedicine at the UMC Utrecht. He is specialized in drug delivery and drug targeting. Currently he coordinates two EU H2020 projects B-Smart & Expert and participates in several EU and national projects on nanomedicine.”
“Professor Jos Malda is Head of Research at the Department of Orthopedics, University Medical Center Utrecht and at the Department of Equine Sciences, University of Utrecht. He also leads the Utrecht Biofabrication Facility.”
Koen de Heus
“Koen de Heus is CEO and shareholding family member of the Royal De Heus Group, an international company with a global top-15 position in the animal nutrition industry. Currently, De Heus has operating activities in 18 countries with a total revenue of 3 billion Euro and 6000 employees. Additionally, De Heus has considerable interests in companies in the value chain to support animal nutrition activities and promote animal health.”
Jeroen de Haas
“Jeroen de Haas is former CEO of sustainable energy company ENECO. De Haas holds several supervisory and advisory roles including chairman of the supervisory board of Royal Wagenborg, member of the supervisory board of Port of Amsterdam, chairman of the board of NPM Energy, and member in the supervisory board of RegMed XB. He is partner in private equity company Prorsum Capital in Zurich. Prorsum invests in three areas of the sustainable development goals: water, mobility, and energy. De Haas focuses in all his activities on the triangle sustainability-innovation-digitization.”
“Ton Logtenberg is founder of Crucell NV and Merus NV and presently occupies the position of non-executive chairman for Synox Therapeutics Ltd. He is on the board of the Jenner Vaccine Foundation, Utrecht Science Park, Hubrecht Organoid Technology Foundation, Forbion European Acquisition Corp, and Mestag Therapeutics. Dr. Logtenberg previously occupied the position of President, Chief Executive Officer & Director at Merus NV, Chief Scientific Officer & Executive VP at Crucell NV and Professor at the University of Utrecht.”
“Dr. Vaccaro has served as the president of the Rothman Orthopedic Institute in Philadelphia since 2014 and is professor and chairman in the Department of Orthopedic Surgery, and professor of Neurosurgery at Thomas Jefferson University Hospital in Philadelphia, USA. He is the president-elect of the Cervical Spine Research Society 2019. Dr. Vaccaro also serves as co-director of the spine surgery residency/fellowship program at Thomas Jefferson University Hospital and Delaware Valley where he instructs current residents and fellows in the diagnosis and treatment of various spinal problems and disorders.”